Has John Salmon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $43 in general payments to John Salmon, MD across 2 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Salmon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Salmon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Salmon, MD

Hematology · Charlotte, NCNPI 1043234370

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $31 of the $43 with a category attached, or 72.4%. AbbVie accounts for 72.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology clinicians in NC, where the typical reported total is $12,876.

$43in general payments, 2019–2025

Across 2 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$31
Gilead$12

$430,065in research payments, 2019–2025

Across 16 payments — averaging $26,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$392K
Amgen$38K

What the payments were for

Food & beverage$3172%
Education$1228%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	1	$31
Gilead	1	$12

How this compares

$43 in reported general payments places this provider in the 10th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$35,916

Medicare patients

118

Services billed

385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ImbruvicaIbrutinib	35	$538,901
Lenalidomide	25	$342,439
RevlimidLenalidomide	14	$249,781
CalquenceAcalabrutinib Maleate	13	$187,798
EliquisApixaban	83	$80,719
XareltoRivaroxaban	62	$43,788
HizentraImmun Glob G(Igg)/Pro/Iga 0-50	13	$38,097
Abiraterone Acetate	17	$24,975
CreonLipase/Protease/Amylase	13	$8,443
Cholestyramine LightCholestyramine	11	$1,505
Imatinib Mesylate	19	$1,477
Oxycodone Hcl	32	$957
Morphine Sulfate ErMorphine Sulfate	26	$776
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	19	$682
Gabapentin	39	$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieCreon	$31	$8,44313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 65 hematology providers in North Carolina.

Other hematology in Charlotte

Ryan JacobsCharlotte$1.5M
Alan Zausner SkarbnikCharlotte$1.1M
Raymond ThertulienCharlotte$561K
Ruben MesaCharlotte$384K
Michael GrunwaldCharlotte$344K
Nilay ShahCharlotte$228K
Peter VoorheesCharlotte$157K
Patricia KropfCharlotte$122K
Arielle HeekeCharlotte$88K
Earle BurgessCharlotte$75K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →